Pablo Corral/LinkedIn
Nov 9, 2025, 01:51
Pablo Corral: A True Game Changer in Lipid Management
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”AHA 2025 | CORALreef Lipids Trial
A true game changer in lipid management.
Enliciditide (MK-0616) – the first oral PCSK9 inhibitor – achieved a 57% LDL-C reduction at week 24 and – 50% sustained at week 52 vs placebo (p<0.001).
- Phase 3 trial, 2,912 patients with ASCVD or at high risk, across 14 countries, with excellent safety profile.
- Takeaway: efficacy and safety comparable to injectable PCSK9 inhibitors — but in a once-daily oral tablet.
- A new era in PCSK9 inhibition and cardiovascular prevention.”
Stay updated with Hemostasis Today.
-
Sep 15, 2026, 15:29Abdul Muqtadir Abbasi: Recognizing Thalassemia Trait Is Essential for Every Physician
-
Sep 15, 2026, 15:17Shehab Mohamed: A New Regional Consensus on HLH Diagnosis and Management
-
Sep 15, 2026, 15:17Sheharyar Raza: Managing Randomness in Artificial Intelligence for Transfusion Medicine
-
Sep 15, 2026, 15:00Sarah Wachtman: Modeling AAV-Based Gene Therapy for Hemophilia A Using Pediatric Liver Organoids
-
Sep 15, 2026, 15:00Ashenafi Tazebew Amare: From Blood Donation to Innovation and Patient Access
-
Sep 15, 2026, 14:56Glanzmann Thrombasthenia Beyond Platelet Transfusion
-
Sep 15, 2026, 14:55Christina Pohlman: The Hidden Complexity of Warfarin Therapy in APS
-
Sep 15, 2026, 14:44Consuela A. Albright: Building a More Connected Sickle Cell Care System
-
Sep 15, 2026, 14:43Andrew Jackson: Cyanosis as a Clue to Central Venous Obstruction